Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Respiration

Volumn 95, Issue 5, 2018, Pages 301-309

  Brunnemer, Eva ^a,b   Wälscher, Julia ^a,b   Tenenbaum, Svenja ^a,b   Hausmanns, Julia ^a,b   Schulze, Karen ^a,b   Seiter, Marianne ^a,b   Heussel, Claus Peter ^b,c,d   Warth, Arne ^a,b   Herth, Felix J F ^a,b   Kreuter, Michael ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEMBER OF THE GERMAN CENTER FOR LUNG RESEARCH DZL   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Idiopathic pulmonary fibrosis; Nintedanib; Real world experience

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PIRFENIDONE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HEALTH SERVICE; HEMATOMA; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SMALL CELL LUNG CANCER; TERTIARY CARE CENTER; TREATMENT DURATION; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 85042730926     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000485933     Document Type: Article

References (28)

1. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Glaser S, Herth FJF, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Frankenberger M, Behr J: Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. Respir Res 2017; 18: 139.
2. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ: Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11:e0151425.
3. Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H, Schnabel PA, Heussel CP, Puderbach M, Herth FJ, Warth A: Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis 2015; 31: 266-274.
4. Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M: Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 2017; 72: 148-153.
5. Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM: Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47: 1776-1784.
6. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U: Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016; 4: 381-389.
7. Tzouvelekis A, Bonella F, Spagnolo P: Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2015; 11: 359-370.
8. Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P: Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. Biomed Res Int 2015; 2015: 329481.
9. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-4782.
10. Woodcock HV, Molyneaux PL, Maher TM: Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther 2013; 7: 503-510.
11. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-1087.
12. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
13. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schunemann HJ; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association: An official ATS/ERS/ JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192:e3-e19.
14. Crestani B, Quaresma M, Kaye M, Stansen W, Stowasser S, Kreuter M: Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS®-ON. Eur Respir J 2016; 48:OA4960.
15. Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, Muller-Quernheim J, Milger K, Prasse A; German Nintedanib Compassionate Use Consortium: Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration 2016; 92: 98-106.
16. Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N: Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med 2016; 5:E78.
17. Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S, Warth A, Herth FJ, Kreuter M: Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207.
18. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
19. Behr J, Gunther A, Ammenwerth W, Bittmann I, Bonnet R, Buhl R, Eickelberg O, Ewert R, Glaser S, Gottlieb J, Grohe C, Kreuter M, Kroegel C, Markart P, Neurohr C, Pfeifer M, Prasse A, Schonfeld N, Schreiber J, Sitter H, Theegarten D, Theile A, Wilke A, Wirtz H, Witt C, Worth H, Zabel P, Muller-Quernheim J, Costabel U: German guideline for diagnosis and management of idiopathic pulmonary fibrosis (in German). Pneumologie 2013; 67: 81-111.
20. Csernus R, Wiebel M, Godeny M, Herth FJ, Kauczor HU, Heussel CP: Hypoxic respiratory failure in chronic lung disease (in German). Med Klin Intensivmed Notfmed 2017; 112: 149-155.
21. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-643.
22. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU: Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
23. Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU: Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71: 429-435.
24. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE Jr, Ryu JH, Collard HR: Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67: 407-411.
25. Funke-Chambour M, Azzola A, Adler D, Barazzone-Argiroffo C, Benden C, Boehler A, Bridevaux PO, Brutsche M, Clarenbach CF, Hostettler K, Kleiner-Finger R, Nicod LP, Soccal PM, Tamm M, Geiser T, Lazor R: Idiopathic pulmonary fibrosis in Switzerland: diagnosis and treatment. Respiration 2017; 93: 363-378.
26. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A: Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-185.
27. Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Kolilekas L, Borie R, Bouros D, Papiris SA: Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract. Respir Med 2016; 117: 14-26.
28. Pfeifer M, Cottin V, Taniguchi H, Richeldi L, Collard HR, Kaye M, Hansell DM, Bailes Z, Schlenker-Herceg R, Raghu G: Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSISTM trials. Pneumologie 2015; 69:P254.